At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Abemaciclibdrug
Likely dose
Abemaciclib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating Abemaciclib for Thyroid Cancer and 2 related conditions. Completed, enrolled 9 participants across 1 site.
Detailed Summary
The purpose of the study is to evaluate the efficacy of treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedSep 2020
Primary CompletionApr 2023
Study CompletionJan 2025
TodayJul 2026
First PostedSep 17, 2020
Enrollment StartSep 10, 2020
Primary CompletionApr 12, 2023
Study CompletionJan 5, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.8 years ago
Interventions
Abemaciclibdrug
200 mg orally